Publications by authors named "R M Navari"

Claim this Profile
I
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting.
Rudolph M Navari, Timothy Tyler, Naoki Inui, Hirotoshi Iihara, Erminio Bonizzoni

Future Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.
Yeon Hee Park, Giampaolo Bianchini, Javier Cortés, Luca Licata, María Vidal, Rudolph M Navari

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial.
Rudolph M Navari, Erminio Bonizzoni

Cancer Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.
J Herrstedt, R Clark-Snow, C H Ruhlmann, A Molassiotis, I Olver, R M Navari

ESMO Open· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.
Jørn Herrstedt, L Celio, P J Hesketh, L Zhang, R Navari

Support Care Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis